Beta-blockers use and risk of breast cancer in women with hypertension
(2021) In Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 30(5). p.965-973- Abstract
BACKGROUND: The risk of breast cancer among hypertensive patients who use beta-blockers has attracted attention. However, the evidence is inconsistent and investigation of the dose-specific associations for subtypes of beta-blockers are limited.
METHODS: By incorporating Swedish national registers, breast cancer risk was estimated in women with hypertension who used nonselective beta-blockers and beta-1 selective blockers compared with propensity score-matched non-users. The cumulative defined daily dose was used to study the dose-response association. Test of interaction between beta-blocker use and other antihypertensive medications was performed.
RESULTS: Hypertensive patients taking beta-1 selective blockers (metoprolol,... (More)
BACKGROUND: The risk of breast cancer among hypertensive patients who use beta-blockers has attracted attention. However, the evidence is inconsistent and investigation of the dose-specific associations for subtypes of beta-blockers are limited.
METHODS: By incorporating Swedish national registers, breast cancer risk was estimated in women with hypertension who used nonselective beta-blockers and beta-1 selective blockers compared with propensity score-matched non-users. The cumulative defined daily dose was used to study the dose-response association. Test of interaction between beta-blocker use and other antihypertensive medications was performed.
RESULTS: Hypertensive patients taking beta-1 selective blockers (metoprolol, atenolol, bisoprolol) had an increased risk of breast cancer with a hazard ratio (HR) and 95% confidence interval (CI) of 2.39 (1.95-2.94), 2.31 (1.46-3.64), and 3.02 (2.09-4.36), respectively. All of the observed associations were dose-dependent (P trend <0.0001). No significant association was found for the nonselective beta-blocker (propranolol) except that among users of agents acting on the renin-angiotensin system, those who used propranolol had increased breast cancer risk. Modification of agents acting on the renin-angiotensin system on breast cancer risk was also observed for atenolol.
CONCLUSION: The increased risk of breast cancer associates with the use of beta-1 selective blockers in a dose-response manner.
IMPACT: Breast cancer surveillance is recommended for hypertensive female patients using beta-1 selective blockers.
(Less)
- author
- Zheng, Guoqiao
LU
; Sundquist, Jan
LU
; Sundquist, Kristina
LU
and Ji, Jianguang
LU
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- volume
- 30
- issue
- 5
- pages
- 965 - 973
- publisher
- American Association for Cancer Research
- external identifiers
-
- scopus:85105427287
- pmid:33619022
- ISSN
- 1538-7755
- DOI
- 10.1158/1055-9965.EPI-20-1599
- language
- English
- LU publication?
- yes
- id
- 9cef66e8-cfd2-466a-905a-85761739921d
- date added to LUP
- 2021-03-20 19:17:17
- date last changed
- 2024-06-27 10:23:43
@article{9cef66e8-cfd2-466a-905a-85761739921d, abstract = {{<p>BACKGROUND: The risk of breast cancer among hypertensive patients who use beta-blockers has attracted attention. However, the evidence is inconsistent and investigation of the dose-specific associations for subtypes of beta-blockers are limited.</p><p>METHODS: By incorporating Swedish national registers, breast cancer risk was estimated in women with hypertension who used nonselective beta-blockers and beta-1 selective blockers compared with propensity score-matched non-users. The cumulative defined daily dose was used to study the dose-response association. Test of interaction between beta-blocker use and other antihypertensive medications was performed.</p><p>RESULTS: Hypertensive patients taking beta-1 selective blockers (metoprolol, atenolol, bisoprolol) had an increased risk of breast cancer with a hazard ratio (HR) and 95% confidence interval (CI) of 2.39 (1.95-2.94), 2.31 (1.46-3.64), and 3.02 (2.09-4.36), respectively. All of the observed associations were dose-dependent (P trend <0.0001). No significant association was found for the nonselective beta-blocker (propranolol) except that among users of agents acting on the renin-angiotensin system, those who used propranolol had increased breast cancer risk. Modification of agents acting on the renin-angiotensin system on breast cancer risk was also observed for atenolol.</p><p>CONCLUSION: The increased risk of breast cancer associates with the use of beta-1 selective blockers in a dose-response manner.</p><p>IMPACT: Breast cancer surveillance is recommended for hypertensive female patients using beta-1 selective blockers.</p>}}, author = {{Zheng, Guoqiao and Sundquist, Jan and Sundquist, Kristina and Ji, Jianguang}}, issn = {{1538-7755}}, language = {{eng}}, number = {{5}}, pages = {{965--973}}, publisher = {{American Association for Cancer Research}}, series = {{Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology}}, title = {{Beta-blockers use and risk of breast cancer in women with hypertension}}, url = {{http://dx.doi.org/10.1158/1055-9965.EPI-20-1599}}, doi = {{10.1158/1055-9965.EPI-20-1599}}, volume = {{30}}, year = {{2021}}, }